OM2 Stock Chart & Stats
€10.30
-€0.30(-1.82%)
At close: 4:00 PM EST
€10.30
-€0.30(-1.82%)
Day’s Range― - ―
52-Week Range€7.55 - €13.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€351.13M
Enterprise Value€487.20M
Total Cash (Recent Filing)€120.28M
Total Debt (Recent Filing)€234.39M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 11, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding40,421,654
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.34
Price to Sales (P/S)0.74
P/FCF Ratio-472.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.11Price Target Upside27.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.02
Revenue Forecast (FY)€738.05M
Bulls Say, Bears Say
Bulls Say
Revenue Base & Accelerating GrowthA robust $825M TTM revenue base with a sharp acceleration in growth indicates improving product adoption across franchises. Durable top-line scale supports investments in R&D and sales, helps absorb fixed costs, and provides a base for sustained margin and cash-flow improvement over the next several quarters.
High And Improving Gross MarginsSustained gross margins near 70% reflect product mix and pricing power in spine and therapeutic device lines. Persistent high gross margins create durable operating leverage as sales scale, enabling margin expansion and funding of launches and commercialization without immediate reliance on external capital.
Product Pipeline And Commercial ExecutionA clear multi-product launch cadence (VIRATA, TrueLok Elevate, Fitbone, 7D) plus distributor prioritization provides durable growth drivers. Successful launches and stronger distributor relationships increase surgeon adoption and recurring procedure-based revenues over multiple quarters, supporting sustainable revenue mix improvement.
Bears Say
Remaining Unprofitable And Weak Free Cash FlowOngoing net losses and slightly negative free cash flow constrain the company’s ability to self-fund product launches, reduce leverage, or absorb one-time costs. Even with operating cash improvements, persistent negative returns limit flexibility and lengthen the timeline to durable, self-sustaining cash generation.
Reimbursement And Policy VulnerabilityMaterial exposure to CMS billing and fee-schedule decisions creates structural revenue and margin volatility for bone growth stimulation products. Regulatory reversals can force outlook resets and impede long-term planning, making future results sensitive to public payor policy shifts beyond company control.
Biologics Underperformance And Segment HeadwindsWeakness in biologics, a higher-value spine component, limits margin expansion and slows portfolio recovery. Delayed biologics traction and flat limb reconstruction growth reduce overall franchise resilience, requiring successful commercial fixes and time to restore multi-quarter contribution to profitability.
Orthofix Medical News
OM2 FAQ
What was Orthofix Medical’s price range in the past 12 months?
Orthofix Medical lowest stock price was €7.55 and its highest was €13.70 in the past 12 months.
What is Orthofix Medical’s market cap?
Orthofix Medical’s market cap is €351.13M.
When is Orthofix Medical’s upcoming earnings report date?
Orthofix Medical’s upcoming earnings report date is Aug 11, 2026 which is in 38 days.
How were Orthofix Medical’s earnings last quarter?
Orthofix Medical released its earnings results on May 05, 2026. The company reported -€0.454 earnings per share for the quarter, beating the consensus estimate of -€0.594 by €0.14.
Is Orthofix Medical overvalued?
According to Wall Street analysts Orthofix Medical’s price is currently Undervalued.
Does Orthofix Medical pay dividends?
Orthofix Medical does not currently pay dividends.
What is Orthofix Medical’s EPS estimate?
Orthofix Medical’s EPS estimate is -0.36.
How many shares outstanding does Orthofix Medical have?
Orthofix Medical has 40,421,654 shares outstanding.
What happened to Orthofix Medical’s price movement after its last earnings report?
Orthofix Medical reported an EPS of -€0.454 in its last earnings report, beating expectations of -€0.594. Following the earnings report the stock price went up 1.523%.
Which hedge fund is a major shareholder of Orthofix Medical?
Currently, no hedge funds are holding shares in DE:OM2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthofix Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.11 (27.33% Upside)
€13.11 (27.33% Upside)
Blogger Sentiment
Neutral
DE:OM2 Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.50%
12-Months-Change
Fundamentals
Return on Equity
-13.44%
Trailing 12-Months
Asset Growth
7.71%
Trailing 12-Months
Company Description
Orthofix Medical
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
OM2 Company Deck
OM2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed steady, disciplined execution with several clear operational and commercial positives: modest top-line growth in Q1, strong performance among top distributors, outperformance in Therapeutic Solutions, improving gross margin, a healthy innovation pipeline (7D, TrueLok Elevate, Fitbone, VIRATA) and reaffirmed full-year guidance. At the same time, challenges persist—Biologics remains soft, U.S. Limb Reconstruction growth was flat, absolute EBITDA was modest, and some results were influenced by timing, mix and prior commercial transitions. Management emphasized that distributor transitions are largely behind them and discussed focused leadership changes and product launches to drive acceleration through the year. Overall, the positives and negatives are balanced, with evidence of improving momentum but meaningful operational work still required.View all DE:OM2 earnings summariesOM2 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€13.11
▲(27.33% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---






